Trials / Completed
CompletedNCT06977880
A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants
A Phase 1, First-in-human Study of MORF-440 in Healthy Participants, Including Single and Multiple Ascending Dose Cohorts
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of single ascending doses of MORF-440 administered to healthy participants single-ascending dose (SAD) and maximum ascending dose (MAD) substudy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY4292009 | Administered orally |
| DRUG | Placebo | Administered orally. |
Timeline
- Start date
- 2025-02-19
- Primary completion
- 2026-03-20
- Completion
- 2026-03-20
- First posted
- 2025-05-18
- Last updated
- 2026-04-17
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT06977880. Inclusion in this directory is not an endorsement.